REGENXBIO stock reports durable gene therapy data from Phase II

Published on 10/04/2026 at 11:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

REGENXBIO stock's latest trial data show a 60 percent three-year response rate on September 24, 2026. Q2 revenue beat consensus by USD 10.39 million.

RGNX, US75901B1070, Illustration mit AI erstellt.

REGENXBIO stock (ISIN US75901B1070) closed at USD 7.42 on Nasdaq on October 1, 2026, down 1.46 percent from the prior close. The latest company catalyst is a three-year gene therapy readout: REGENXBIO reported the data on September 24, 2026.

Three-year data reaches 60 percent

In the Phase II ALTITUDE study, 60 percent of Dose Level 3 participants with three-year visits, or 6 of 10 people, achieved more than a two-step improvement on the Diabetic Retinopathy Severity Scale without additional treatment. The same group recorded no vision-threatening events, while 3 of 4 participants with a one-step improvement at one year later reached the more than two-step threshold at three years, according to REGENXBIO.

The safety signal is also relevant for the program's next stage. No intraocular inflammation was observed through three years among 17 participants receiving short-course prophylactic topical steroids, although the readout remains Phase II evidence rather than a regulatory approval.

Q2 revenue beat consensus

The financial picture added a second quantified support point. MarketBeat reported that second-quarter 2026 revenue reached USD 108.02 million versus USD 97.63 million expected, a USD 10.39 million beat. EPS was USD 0.43 versus USD 0.08 consensus, while the company still faces a forecast full-year loss of USD 3.91 per share.

Analysts see a wide target gap

MarketBeat reported a Moderate Buy consensus on September 23, 2026, based on 13 analysts: nine Buy ratings, three Holds and one Sell. The average 12-month price target was USD 23.27, leaving the October 1 reference price 68.1 percent below that target.

Stock stays below its yearly high

REGENXBIO had a market capitalization of USD 384.1 million and trading volume of 1,035,162 shares as of October 2, 2026. Its 52-week range was USD 5.46 to USD 16.19, placing the October 1 close USD 8.77 below the yearly high and USD 1.96 above the low.